Recent Investment Analysts’ Ratings Updates for Sarepta Therapeutics (SRPT)

A number of firms have modified their ratings and price targets on shares of Sarepta Therapeutics (NASDAQ: SRPT) recently:

• 5/8/2025 – Sarepta Therapeutics had its price target lowered by analysts at Wells Fargo & Company from $115.00 to $100.00. They now have an “overweight” rating on the stock.
• 5/8/2025 – Sarepta Therapeutics was downgraded by analysts at Evercore ISI from an “outperform” rating to an “inline” rating. They now have a $50.00 price target on the stock.
• 5/7/2025 – Sarepta Therapeutics had its price target lowered by analysts at Royal Bank of Canada from $87.00 to $58.00. They now have a “sector perform” rating on the stock.
• 5/7/2025 – Sarepta Therapeutics had its price target lowered by analysts at Cantor Fitzgerald from $163.00 to $81.00. They now have an “overweight” rating on the stock.
• 5/7/2025 – Sarepta Therapeutics had its price target lowered by analysts at Piper Sandler from $110.00 to $70.00. They now have an “overweight” rating on the stock.
• 5/7/2025 – Sarepta Therapeutics had its price target lowered by analysts at Morgan Stanley from $182.00 to $113.00. They now have an “overweight” rating on the stock.
• 5/7/2025 – Sarepta Therapeutics had its price target lowered by analysts at Oppenheimer Holdings Inc. from $184.00 to $123.00. They now have an “outperform” rating on the stock.
• 5/7/2025 – Sarepta Therapeutics had its price target lowered by analysts at HC Wainwright from $75.00 to $40.00. They now have a “neutral” rating on the stock.
• 5/7/2025 – Sarepta Therapeutics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $178.00 to $100.00. They now have a “buy” rating on the stock.
• 5/7/2025 – Sarepta Therapeutics had its price target lowered by analysts at Guggenheim from $112.00 to $98.00. They now have a “buy” rating on the stock.
• 5/7/2025 – Sarepta Therapeutics had its price target lowered by analysts at Needham & Company LLC from $183.00 to $125.00. They now have a “buy” rating on the stock.
• 4/21/2025 – Sarepta Therapeutics had its price target lowered by analysts at Piper Sandler from $182.00 to $110.00. They now have an “overweight” rating on the stock.
• 4/16/2025 – Sarepta Therapeutics had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
• 4/11/2025 – Sarepta Therapeutics had its price target lowered by analysts at Morgan Stanley from $196.00 to $182.00. They now have an “overweight” rating on the stock.
• 4/11/2025 – Sarepta Therapeutics is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $115.00 price target on the stock.
• 4/3/2025 – Sarepta Therapeutics had its price target lowered by analysts at Needham & Company LLC from $202.00 to $183.00. They now have a “buy” rating on the stock.
• 4/2/2025 – Sarepta Therapeutics was upgraded by analysts at HC Wainwright from a “sell” rating to a “neutral” rating. They now have a $75.00 price target on the stock.
• 3/31/2025 – Sarepta Therapeutics was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $87.00 price target on the stock, down previously from $161.00.
• 3/20/2025 – Sarepta Therapeutics had its price target lowered by analysts at Scotiabank from $105.00 to $80.00. They now have a “sector perform” rating on the stock.
• 3/19/2025 – Sarepta Therapeutics had its “sell” rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
• 3/19/2025 – Sarepta Therapeutics had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $124.00 to $99.00. They now have a “hold” rating on the stock.
• 3/18/2025 – Sarepta Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $163.00 price target on the stock.
• 3/18/2025 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $202.00 price target on the stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $36.27 on Monday. The company has a market capitalization of $3.56 billion, a price-to-earnings ratio of 29.02 and a beta of 0.85. Sarepta Therapeutics, Inc. has a 52 week low of $35.46 and a 52 week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm has a 50 day moving average of $66.84 and a 200 day moving average of $100.44.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The business’s quarterly revenue was up 80.2% on a year-over-year basis. During the same period last year, the firm earned $0.73 EPS. On average, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now directly owns 27,812 shares of the company’s stock, valued at $2,771,187.68. The trade was a 8.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds have recently added to or reduced their stakes in SRPT. Manchester Capital Management LLC boosted its holdings in Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 156 shares during the last quarter. Byrne Asset Management LLC acquired a new stake in Sarepta Therapeutics in the 1st quarter valued at about $30,000. Center for Financial Planning Inc. acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $31,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $36,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.